References
- The Korea Center for Disease Control and Prevention. Recent trends in national notifiable diseases occurrence based on the data of 2003. Communicable Diseases Monthly Report 2004;15:129-37
- Kim SH, Kim JY, Kang YH, Park YK, Lee BK. Occurrence of extended-spectrum beta-lactamases in members of the genus Shigella in the Republic of Korea. J Clin Microbiol 2004;42:5264-9 https://doi.org/10.1128/JCM.42.11.5264-5269.2004
- The Korea Center for Disease Control and Prevention. The first domestic outbreak of ESBL producing Shigella sonnei. Communicable Diseases Monthly Report 2004;15:252
- Ho PL, Shek RH, Chow KH, Duan RS, Mak GC, Lai EL, et al. Detection and characterization of extended-spectrum beta-lactamases among bloodstream isolates of Enterobacter spp. in Hong Kong, 2000-2002. J Antimicrob Chemother 2005;55:326-32
- MEGA. molecular evolutionary genetics analysis[computer program]. version 1.01. Pennsylvania State University, University Park; 1993.
- The Korea Center for Disease Control and Prevention. The outbreak of ESBL producing Shigella sonnei. Communicable Diseases Monthly Report 2005;16:1-5
- Cleary TG. Shigella. In : Feigin RD, Cherry JD, Demmler GJ, Kaplan SL, editors. Textbook of pediatric infectious diseases. 5th ed. Philadelphia : WB Saunders Co, 2004:1459-69
- Dupont HL. Shigella species(Bacillary dysentery). In : Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 6th ed. Philadelphia : Elsevier Churchill Livingstone Co, 2004:2655-61
- Thielman NM, Guerrant RL. Clinical practice. Acute infectious diarrhea. N Engl J Med 2004;350:38-47 https://doi.org/10.1056/NEJMcp031534
- Guerrant RL, Van Gilder T, Steiner TS, Thielman NM, Slutsker L, Tauxe RV, et al. Practice guidelines for the management of infectious diarrhea. Clin Infect Dis 2001;32:331-51 https://doi.org/10.1086/318514
- Salam MA, Bennish ML. Therapy for shigellosis. I. Randomized double-blind trial of nalidixic acid in childhood shigellosis. J Pediatr 1988;113:901-7 https://doi.org/10.1016/S0022-3476(88)80029-5
- Bennish ML, Salam MA, Haider R, Barza M. Therapy for shigellosis. II. Randomized, double-blind comparison of ciprofloxacin and ampicillin. J Infect Dis 1990;162:711-6 https://doi.org/10.1093/infdis/162.3.711
- Bennish ML, Salam MA, Khan WA, Khan AM. Treatment of shigellosis : III. Comparison of one- or two-dose ciprofloxacin with standard 5-day therapy. A randomized, blinded trial. Ann Intern Med 1992;117:727-34 https://doi.org/10.7326/0003-4819-117-9-727
- Salam MA, Seas C, Khan WA, Bennish ML. Treatment of shigellosis : IV. Cefixime is ineffective in shigellosis in adults. Ann Intern Med 1995;123:505-8 https://doi.org/10.7326/0003-4819-123-7-199510010-00005
- Khan WA, Seas C, Dhar U, Salam MA, Bennish ML. Treatment of shigellosis : V. Comparison of azithromycin and ciprofloxacin. A double-blind, randomized, controlled trial. Ann Intern Med 1997;126:697-703 https://doi.org/10.7326/0003-4819-126-9-199705010-00004
- Prado D, Liu H, Velasquez T, Cleary TG. Comparative efficacy of pivmecillinam and cotrimoxazole in acute shigellosis in children. Scand J Infect Dis 1993;25:713-9 https://doi.org/10.3109/00365549309008568
- Salam MA, Dhar U, Khan WA, Bennish ML. Randomized comparison of ciprofloxacin suspension and pivmecillinam for childhood shigellosis. Lancet 1998;352:522-7 https://doi.org/10.1016/S0140-6736(97)11457-X
- Helvaci M, Bektaslar D, Ozkaya B, Yaprak I, Umurtak B, Ertugrul A. Comparative efficacy of cefixime and ampicillin-sulbactam in shigellosis in children. Acta Paediatr Jpn 1998;40:131-4 https://doi.org/10.1111/j.1442-200X.1998.tb01896.x
- Shanks GD, Smoak BL, Aleman GM, Oundo J, Waiyaki PG, Dunne MW, et al. Single dose of azithromycin or three-day course of ciprofloxacin as therapy for epidemic dysentery in Kenya. Acute dysentery study group. Clin Infect Dis 1999;29:942-3 https://doi.org/10.1086/520469
- Kabir I, Butler T, Khanam A. Comparative efficacies of single intravenous doses of ceftriaxone and ampicillin for shigellosis in placebo-controlled trial. Antimicrob Agents Chemother 1986;29:645-8 https://doi.org/10.1128/AAC.29.4.645
- Martin JM, Pitetti R, Maffei F, Tritt J, Smail K, Wald ER. Treatment of shigellosis with cefixime : two days vs. five days. Pediatr Infect Dis J 2000;19:522-6 https://doi.org/10.1097/00006454-200006000-00006
- Oldfield EC 3rd, Wallace MR, The role of antibiotics in the treatment of infectious diarrhea. Gastroenterol Clin North Am 2001;30:817-36 https://doi.org/10.1016/S0889-8553(05)70212-0
- Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, et al. Bloodstream infections due to extended spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae : risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother 2004;48:4574-81 https://doi.org/10.1128/AAC.48.12.4574-4581.2004
- Nakamura T, Komatsu M. Susceptibility of ESBL-producing Escherichia coli and Klebsiella pneumoniae to various antibiotic agents. Jpn J Antibiot 2005;58:1-10 https://doi.org/10.1038/ja.2005.1
-
The Korea Center for Disease Control and Prevention. Extended-spectrum
${\beta}$ -lactamase. Communicable Diseases Monthly Report 2001;12:45-8 -
Pitout JD, Sanders CC, Sanders WE Jr. Antimicrobial resistance with focus on
${\beta}$ -lactam resistance in gramnegative bacilli. Am J Med 1997;103:51-9 https://doi.org/10.1016/S0002-9343(97)00044-2 -
Jacoby GA. Epidemiology of extended-spectrum
${\beta}$ -lactamases. Clin Infect Dis 1998;27:81-3 https://doi.org/10.1086/514644 -
Rice L. Evolution and clinical importance of extended-spectrum
${\beta}$ -lactamases. Chest 2001;119(2 Suppl):391S-6S https://doi.org/10.1378/chest.119.2_suppl.391S -
Bush K. New
${\beta}$ -lactamases in gram-negative bacteria : diversity and impact on the selection of antimicrobial therapy. Clin Infect Dis 2001;32:1085-9 https://doi.org/10.1086/319610 -
Colodner R. Extended-spectrum
${\beta}$ -lactamases : a challenge for clinical microbiologists and infection control specialists. Am J Infect Control 2005;33:104-7 https://doi.org/10.1016/j.ajic.2004.07.010 -
Pai H, Choi EH, Lee HJ, Hong JY, Jacoby GA. Identification of CTX-M-14 extended-spectrum
${\beta}$ -lactamase in clinical isolates of Shigella sonnei, Escherichia coli, and Klebsiella pneumoniae in Korea. J Clin Microbiol 2001;39:3747-9 https://doi.org/10.1128/JCM.39.10.3747-3749.2001 -
Neu HC, Saha G, Chin NX. Comparative in vitro activity and
${\beta}$ -lactamase stability of FK482, a new oral cephalosporin. Antimicrob Agents Chemother 1989;33:1795-800 https://doi.org/10.1128/AAC.33.10.1795 - Chatterjee A, Moland ES, Thomson KS. Cefdinir : An oral alternative to parenteral cephems. Diagn Microbiol Infect Dis 2005;51:259-64 https://doi.org/10.1016/j.diagmicrobio.2004.11.015
- Rupp ME, Fey PD. Extended spectrum beta-lactamase(ESBL)-producing Enterobacteriacea : considerations for diagnosis, prevention and drug treatment. Drugs 2003;63:353-65 https://doi.org/10.2165/00003495-200363040-00002
- Stapleton P, Wu PJ, King A, Shannon K, French G, Phillips I. Incidence and mechanism of resistance to the combination of amoxicillin and clavulanic acid in Escherichia coli. Antimicrob Agents Chemother 1995;39:2478-83 https://doi.org/10.1128/AAC.39.11.2478
- Burkhardt JE, Walterspiel JN, Schaad UB. Quinolone arthropathy in animals versus children. Clin Infect Dis 1997;25:1196-204 https://doi.org/10.1086/516119
- Hampel B, Hullmann R, Schmidt H. Ciprofloxacin in pediatrics : worldwide clinical experience based on compassionate use-safety report. Pediatr Infect Dis J 1997;16:127-9 https://doi.org/10.1097/00006454-199701000-00036
- The Zimbabwe, Bangladesh, South africa(Zimbasa) Dysentery Study Group. Multicenter, randomized, double blind clinical trial of short course versus standard course oral ciprofloxacin for Shigella dysenteriae type 1 dysentery in children. Pediatr Infect Dis J 2002;21:1136-41 https://doi.org/10.1097/00006454-200212000-00010
- Jacoby GA, Chow N, Waites KB. Prevalence of plasmid-mediated quinolone resistance. Antimicrob Agents Chemother 2003;47:559-62 https://doi.org/10.1128/AAC.47.2.559-562.2003
- Rakita RM, Jacques-Palaz K, Murray BE. Intracellular activity of azithromycin against bacterial enteric pathogens. Antimicrob Agents Chemother 1994;38:1915-21 https://doi.org/10.1128/AAC.38.9.1915